Role of embolic protection devices in ostial saphenous vein graft lesions

Background Although embolic protection devices (EPDs) have been shown to be beneficial in saphenous vein graft (SVG) lesions, their role in the subgroup of ostial SVG lesions has received limited study. Methods The coronary angiograms and procedural outcomes of 109 patients undergoing stenting of 11...

Full description

Saved in:
Bibliographic Details
Published inCatheterization and cardiovascular interventions Vol. 80; no. 7; pp. 1120 - 1126
Main Authors Abdel-Karim, Abdul-Rahman R., Papayannis, Aristotelis C., Mahmood, Arif, Michael, Tesfaldet T., Rangan, Bavana V., Makke, Lorenza, Banerjee, Subhash, Brilakis, Emmanouil S.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.12.2012
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Although embolic protection devices (EPDs) have been shown to be beneficial in saphenous vein graft (SVG) lesions, their role in the subgroup of ostial SVG lesions has received limited study. Methods The coronary angiograms and procedural outcomes of 109 patients undergoing stenting of 113 ostial SVG lesions were retrospectively reviewed to determine the frequency of EPD use and the periprocedural outcomes. Results Ninety‐eight (87%) of the 113 lesions were suitable for EPD use, that was used in 70 lesions (71%). A Filterwire (Boston Scientific) or a SPIDER (ev3) filter were used in 54 (77%) and 16 (23%) of lesions, respectively. Difficulty retrieving the filter post stenting was encountered in eight lesions (11%) and led to stent thrombosis causing cardiac arrest in one patient (1%). Angiographic success was achieved in 111 (98%) of 113 lesions. Conclusions EPDs can be utilized in the majority of ostial SVG lesions, but in 11% of cases filter retrieval can be challenging and may rarely (in approximately 1%) lead to a significant complication. © 2012 Wiley Periodicals, Inc.
Bibliography:istex:88598BE62458EB157EDC911EA36A526B4259BB7E
ark:/67375/WNG-9LX9QL63-M
Conflict of interest: Dr. Banerjee: speaker honoraria from St. Jude Medical, Medtronic, and Johnson & Johnson and research support from Boston Scientific and The Medicines Company. Dr. Brilakis: speaker honoraria from St Jude Medical and Terumo; research support from Abbott Vascular; spouse is an employee of Medtronic.
ArticleID:CCD23471
Conflict of interest: Dr. Banerjee: speaker honoraria from St. Jude Medical, Medtronic, and Johnson & Johnson and research support from Boston Scientific and The Medicines Company.
Dr. Brilakis: speaker honoraria from St Jude Medical and Terumo; research support from Abbott Vascular; spouse is an employee of Medtronic.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.23471